Indian court blocks Glenmark's cut-price Januvia, expedites patent case

India's Supreme Court has blocked any fresh manufacture by Glenmark of its cut-price version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride).

More from Alimentary/Metabolic

More from Therapy Areas